Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET

Company Participants

Karen Hunady - Director, IR and Corporate Communications

Nancy Simonian - President and CEO

David Roth - CMO

Jason Haas - CFO

Conley Chee - CCOO

Conference Call Participants

Ted Tenthoff - Piper Sandler

Phil Nadeau - TD Cowen

Operator

Good morning, and welcome to Syros Pharmaceuticals' Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen only mode. This call is being webcast live on the Investors and Media section of Syros' website at www.syros.com. Please be advised that today's call is being recorded.

At this time, I would like to turn the call over to Karen Hunady, Director of Investor Relations and Corporate Communications at Syros. Please go ahead.

Karen Hunady

Thank you. This morning we issued a press release announcing our second quarter 2023 financial results. The full release is available on the Investors and Media section of Syros' website at www.syros.com.

We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer; Dr. David Roth, our Chief Medical Officer; and Jason Hass, our Chief Financial Officer. We will then open the call for questions. Kristin Stephens, our Chief Development Officer; Dr. Eric Olson, our Chief Scientific Officer; and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A.

Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our quarterly report on Form 10-Q that we filed this morning, our annual report on Form 10-K that we filed earlier in the year, and any other filings that we may make with the SEC in the future.

Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

I would now like to turn the call over to Nancy. Nancy?

Nancy Simonian

Thank you, Karen. Good morning everyone and thank you for joining us today. The first half of the year has been very productive for Syros and we are encouraged by ongoing momentum across our clinical trials and our precommercial activities.